Skip to main content

Day: July 1, 2022

Hofseth Biocare ASA: CONTEMPLATED PRIVATE PLACEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 1 July 2022) Hofseth Biocare ASA (“HBC” or the “Company”) has resolved to effect a contemplated private placement of new shares, after the close of trading on Oslo Børs today (the “Private Placement”). The Private Placement is directed towards Norwegian and international investors, subject to applicable exemptions from relevant registration, filing and prospectus requirements, and subject to other applicable selling restrictions. The minimum application and allocation amount...

Continue reading

Porsche reports Q2 2022 U.S. retail sales

First-half deliveries to customers total more than 32,529 new cars across all model linesPorsche reports Q2 2022 U.S. retail sales 2022 Porsche Cayenne Turbo GTAtlanta, July 01, 2022 (GLOBE NEWSWIRE) — Porsche Cars North America, Inc. (PCNA) today announced U.S. retail deliveries in the second quarter of 2022 totaled 19,487, up 2.8 percent from the same period one year ago, despite ongoing supply issues in the wider economy. In the first six months, U.S. retail deliveries totaled 32,529 or 10.5 percent down from the first half of 2021, which was the strongest sales year in PCNA’s history. “Performance is a key part of Porsche culture and we are working closely across the company as one team to meet the demand from our U.S. customers,” said Kjell Gruner, President and CEO of PCNA. “Our order books are full as we attract new...

Continue reading

Information on share capital and voting rights – June 2022

Information on share capital and voting rights June 2022 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. July 1st, 2022 Statement made by: Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)Date   Total number of shares   Total number of voting rightsTheorical (1) Exercisable (2)June 30th, 2022 43,755,627 43,755,627 43,238,070(1)   Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2)    For information, excluding treasury shares stripped of voting rights, excluding liquidity contract. Provision of Nexans articles of association requiring...

Continue reading

Half-year statement on Nexans liquidity contract – January 1st to June 30th, 2022

PRESS RELEASE _ HALF–YEAR LIQUIDITY CONTRACT STATEMENT FOR NEXANS Paris La Défense, on July 1st, 2022 – Pursuant to the liquidity contract granted by NEXANS (ISIN code: FR0000044448, NEX) to ODDO BHF SCA and Natixis, the following assets appeared on the dedicated liquidity account as of June 30th, 2022:34,057 shares EUR 3,857,878.93 in cash Number of purchase transactions executed over the semester: 2,155 Number of sales transactions executed over the semester: 2,101 Volume traded over the semester for purchase: 261,343 shares for EUR 21,656,605.45 Volume traded over the semester for sales: 255,237 shares for EUR 21,541,639.45As a reminder, the following assets appeared on the last half-year report as of December 31st, 2021, on the dedicated liquidity account:27,951 shares EUR 3,972,843.89 in cash Number of purchase transactions...

Continue reading

Mizuho acquires Dallas-based Capstone Partners

NEW YORK, July 01, 2022 (GLOBE NEWSWIRE) — Mizuho Americas today announced the completion of its acquisition of Capstone Partners, a leading independent, middle-market placement agent focused on fundraising and advisory services to private equity, credit, real assets, and infrastructure investment firms. The deal expands Mizuho Americas’ suite of investment banking solutions for clients in the alternative investment market, specifically financial sponsors. “Capstone reinforces our global capital raising and distribution capabilities, while opening new avenues of opportunity for delivering innovative fundraising and advisory services to the financial sponsor and general partner markets,” said Jerry Rizzieri, President and CEO of Mizuho Securities USA. “The acquisition also enhances our pipeline for lending, acquisition financing,...

Continue reading

Form 8.3 – [LXi REIT plc – 30 06 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LXI REIT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [Ideagen plc – 30 06 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDEAGEN PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDEAGEN PLC AS AN ASSOCIATE OF THE...

Continue reading

Form 8.3 – [EMIS Group plc – 30 06 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [CareTech Holdings plc – 30 06 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CARETECH HOLDINGS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic

Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccine Doses will be manufactured using existing bulk vaccine from previous orders from BARDA Deliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. Deliveries under this contract will start in the fourth quarter of 2022 and continue through early 2023. This order comes a few weeks after...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.